Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2016 (2016), Article ID 6151570, 4 pages
http://dx.doi.org/10.1155/2016/6151570
Case Report

On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series

1Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, 135 Rutledge Avenue Suite 1209, MSC 752, Charleston, SC 29425, USA
2Department of Pharmacy Services, Medical University of South Carolina, 150 Ashley Avenue, Charleston, SC 29425, USA
3Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, USA
4Division of Gastroenterology and Hepatology, Department of Medicine, Medical University of South Carolina, 114 Doughty Street Suite 249, MSC 702, Charleston, SC 29425, USA

Received 24 March 2016; Accepted 8 May 2016

Academic Editor: Tomoyuki Shibata

Copyright © 2016 Madelyne Bean et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Eradication of chronic hepatitis C virus (HCV) infection is now possible with all oral antiviral medications, including the combination of ombitasvir, paritaprevir, dasabuvir, and ritonavir (PrOD) with or without ribavirin. While high rates of sustained virologic response (SVR) can be achieved, a small subset of patients experience on-treatment liver enzyme elevations, in particular women using concurrent estradiol-containing oral contraceptive medications (OCPs). Herein, we describe four cases of liver enzyme elevations within 2-3 weeks of PrOD initiation in African-American men infected with HCV genotype 1a or 1b. Three patients with varying degrees of hepatic fibrosis received a full treatment course without medication modification, achieved SVR, and experienced resolution of liver enzyme abnormalities. One patient with cirrhosis was switched mid-treatment to an alternate HCV regimen, experienced subsequent resolution of liver enzyme abnormalities, and achieved SVR. In summary, these cases suggest that all HCV patients treated with PrOD, independent of gender or concurrent medications, should have laboratory monitoring for liver enzyme elevations, with a particular emphasis on early monitoring in cirrhotic patients.